14 mei 2025: Howard Walton is een prostaatkankerpatiënt die in 2022 werd gediagnosteerd met prostaatkanker en werd behandeld in het MD Anderson Cancer Center met HIFU - High Intensity Focused Ultrasound. Lees hier zijn ervaringsverhaal
14 mei 2025: Bron: Journal of Endourology, Published Online: 1 April 2017
HIFU - High Intensity Focused Ultrasound transrectaal toegepast en al of niet gecombineerd met hormoontherapie, geeft uitstekende resultaten op overall overleving bij prostaatkankerpatiënten in alle stadia. Zowel curatief als palliatief gegeven levert HIFU - High Intensity Focused Ultrasound een veel betere kwaliteit van leven en overall overlevingspercentages van boven de 90 procent, zowel na metingen op 5 jaar en 10 jaar na de toediening van HIFU - HIFU - High Intensity Focused Ultrasound. Bovendien wordt deze behandeling uitstekend verdragen door patiënten en geeft nauwelijks bijwerkingen, niet op korte termijn en niet op de langere termijn. HIFU - High Intensity Focused Ultrasound is bewezen een veilige en effectieve behandeling
Dat blijkt uit een reviewstudie over de afgelopen 25 jaar in het MD Anderson Cancer Center.
Een recent gepubliceerde studie (d.d. 2024) publiceerde de resultaten van een studie waaraan 113 prostaatkankerpatiënten met stadium T3-T4 deelnamen, die gedurende een mediane tijd van 4,6 jaar werden gevolgd. zie referentie 22
De mediane PSA-snelheid van deze groep van patiënten was 0,19 ng/ml/jaar en de prostaatkankerspecifieke overleving was 96,4%.
Een andere studie rapporteerde de resultaten van 55 mannen met PSA-progressie en lokaal biopsie-bewezen tumorrecidief tijdens een definitieve hormonale ablatietherapie die HIFU - High Intensity Focused Ultrasound kregen voor hormoonresistente prostaatkanker. (Zie referentie 23 )
Met een mediane follow-up tijd van 21 maanden bedroeg de prostaatkankerspecifieke overleving 87,3%.
Voor overzicht van studies uit de reviewsudie met prostaatkankerpatiënten met lokale ziekte en lage
Gleasonscores en prostaatkankerpatiënten met reeds gevorderde en uitgezaaide ziekte en hoge Gleasonscores zie Tables 1 en 2.
De reviewstudie geeft een mooie beschrijving ook van de geschiedenis en ontwikkeling van HIFU - High Intensity Focused Ultrasound en beschrijft zowel diagnostisch toegepast als genezend als palliatief. Het studieverslag is gratis in te zien of te downlaoden. Klik op de titel van het abstract:
De reviewstudie geeft een mooie beschrijving ook van de geschiedenis en ontwikkeling van HIFU - High Intensity Focused Ultrasound en beschrijft zowel diagnostisch toegepast als genezend als palliatief. Het studieverslag is gratis in te zien of te downlaoden. Klik op de titel van het abstract:
High-Intensity Focused Ultrasound for the Treatment of Prostate Cancer: A Review
Publication: Journal of Endourology
https://doi.org/10.1089/end.2016.0548
Abstract
Over the past 25 years, the average life expectancy for men has increased almost 4 years, and the age of prostate cancer detection has decreased an average of 10 years with diagnosis increasingly made at early-stage disease where curative therapy is possible. These changing trends in the age and extent of malignancy at diagnosis have revealed limitations in conventional curative therapies for prostate cancer, including a significant risk of aggressive cancer recurrence, and the risk of long-term genitourinary morbidity and its detrimental impact on patient's quality of life (QOL). Greater awareness of the shortcomings in radical prostatectomy, external radiotherapy, and brachytherapy has prompted the search for alternative curative therapies that offer comparable rates of cancer control and less treatment-related morbidity to better preserve QOL. High-intensity focused ultrasound (HIFU) possesses characteristics that make it an attractive curative therapy option. HIFU is a noninvasive approach that uses precisely delivered ultrasound energy to achieve tumor cell necrosis without radiation or surgical excision. In current urologic oncology, HIFU is used clinically in the treatment of prostate cancer and is under experimental investigation for therapeutic use in multiple malignancies. Clinical research on HIFU therapy for localized prostate cancer began in the 1990s, and there have now been ∼65,000 prostate cancer patients treated with HIFU, predominantly with the Ablatherm (EDAP TMS, Lyon, France) device. Neoadjuvant transurethral resection of the prostate has been combined with HIFU since 2000 to reduce prostate size, facilitate tissue destruction, and to minimize side effects. Advances in imaging technologies are expected to further improve the already superior efficacy and morbidity outcomes, and ongoing investigation of HIFU as a focal therapy in salvage and palliative indications is serving to expand the role of HIFU as a highly versatile noninvasive therapy for prostate cancer.
- Abstract
- The Clinical History of High-Intensity Focused Ultrasound
- HIFU Mechanisms and Technology
- Indications for HIFU Therapy of Prostate Cancer
- Combining TURP and HIFU
- Efficacy of HIFU as Primary Therapy
- HIFU as Salvage Therapy
- Focal and Partial HIFU Therapy
- Immunologic Response with HIFU Therapy
- Future Directions of HIFU for Prostate Cancer
- Conclusion
- Abbreviations Used
- References
References
1.
Chaussy C, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003;4:248–252.
2.
Chaussy C, Thuroff S. Results and side effects of high intensity focused ultrasound in localized prostate cancer. J Endourol 2001;15:437–440, 447–448.
3.
Chaussy Ch, Thuroff S. The use of high-intensity focused ultrasound in prostate cancer. In: Ukimura O, Gill IS. Contemporary Interventional Ultrasonography in Urology. London: Springer, 2009, pp. 63–74.
4.
Lynn JG, Putman TJ. Histological and cerebral lesions produced by focused ultrasound. Am J Pathol 1944;20:637–649.
5.
Chaussy C, Thüroff S, Rebillard X, Gelet A. Technology insight: High-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2005;2:191–198.
6.
ter Haar G. Intervention and therapy. Ultrasound Med Biol 2000;23(1 Suppl): S51–S54.
7.
Chaussy CG, Thüroff SF. Robotic high-intensity focused ultrasound for prostate cancer: What have we learned in 15 years of clinical use? Curr Urol Rep 2011;12:180–187.
8.
Chaussy C, Thüroff S. High-intensity focused ultrasound in the management of prostate cancer. Expert Rev Med Devices 2010;7:209–217.
9.
Chapelon JY, Margonari J, Theillère Y, Gorry F, Vernier F, Blanc E, Gelet A. Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. Eur Urol 1992;22:147–152.
10.
Uchida T, Sanghvi NT, Gardner TA, et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: A preliminary report. Urology 2002;59:394–398; discussion 398–399.
11.
Chapelon JY, Cathignol D, Cain C, et al. New piezoelectric transducers for therapeutic ultrasound. Ultrasound Med Biol 2000;26:153–159.
12.
Chaussy CG, Thüroff S. High-intensive focused ultrasound in localized prostate cancer. J Endourol 2000;14:293–299.
13.
Oosterhof GO, Cornel EB, Smits GA, Debruyne FM, Schalken JA. Influence of high intensity focused ultrasound on the development of metastases. Eur Urol 1997;32:91–95.
14.
Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Cathignol D, Blanc E. Prostatic tissue destruction by high-intensity focused ultrasound: Experimentation on canine prostate. J Endourol 1993;7:249–253.
15.
Chaussy CG, Thüroff S. Robot-assisted high-intensity focused ultrasound in focal therapy of prostate cancer. J Endourol 2010;24:843–847.
16.
Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouvière O, Curiel L, Janier M, Vallancien G. Local recurrence of prostate cancer after external beam radiotherapy: Early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63:625–629.
17.
Chaussy C, Thueroff S. Complete remission in metastatic prostate cancer after combined local and systemic therapy. Urology 2006;68:197–198.
18.
Chaussy CG, Thueroff S. Transrectal high-intensity focused ultrasound for local treatment of prostate cancer. Urologe A 2009;48:710–718.
19.
Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: Feasibility study. J Urol 2004;171:2265–2267.
20.
Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and outcomes. Cancer 2008;112:307–314.
21.
Thüroff S, Chaussy CG. High-intensity focused ultrasound: Complications and adverse events. Mol Urol 2000;4:183–187.
22.
Chaussy CG, Thueroff SF. HIFU treatment of locally advanced prostate cancer. J Endourol 2010;24(1 Suppl):A86.
23.
Chaussy C, Thuroff S, Nanieva R. Hormone resistant prostate cancer treated by robotic high intensive ultrasound. J Urol 2010;(183 Suppl):e262.
24.
Chaussy C, Thüroff S, Bergsdorf T. Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option. Urologe A 2006;45:1271–1275.
25.
Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 2009;55:640–647.
26.
van Leeuwen PJ, Connolly D, Tammela TL, Auvinen A, Kranse R, Roobol MJ, Schroder FH, Gavin A. Balancing the harms and benefits of early detection of prostate cancer. Cancer 2010;116:4857–4865.
27.
Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schröder FH. Nomogram use for the prediction of indolent prostate cancer: Impact on screen-detected populations. Cancer 2007;110:2218–2221.
28.
Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H, Jin CB. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol 2004;30:1217–1222.
29.
Hu Z, Yang XY, Liu Y, et al. Investigation of HIFU-induced antitumor immunity in a murine tumor model. J Transl Med 2007;5:34.
30.
Orzyk K, Emberton M, Ahmed HU. What tumours should we treat with focal therapy based on risk category, grade, size and location? Curr Opin Urol 2015;25:212–219.
31.
Thueroff S, Chaussy C, Transrectal prostate cancer ablation by robotic high-intensity focused ultrasound (HIFU) at 3 MHz: 18 years clinical experiences. In: Thüroff S, Chaussy C, eds. Focal Therapy of Prostate Cancer. An Emerging Strategy for Minimally Invasive, Staged Treatment. Switzerland: Springer International Publishing, 2015.
32.
Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lyonnet D, Dubernard JM. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: Factors influencing the outcome. Eur Urol 2001;40:124–129.
33.
Poissonnier L, Gelet A, Chapelon JY, Bouvier R, Rouviere O, Pangaud C, Lyonnet D, Dubernard JM. Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10 ng/ml). Prog Urol 2003;13:60–72.
34.
Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381–387.
35.
Thüroff S, Chaussy C, Vallancien G, et al. High-intensity focused ultrasound and localized prostate cancer: Efficacy results from the European multicentric study. J Endourol 2003;17:673–677.
36.
Blana A, Walter W, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004;63:297–300.
37.
Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, Walter B. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008;72:1329–1333.
38.
Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008;53:1194–1201.
39.
Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martignoni G, Artibani W. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 2006;98:1193–1198.
40.
Ganzer R, Fritsche HM, Brandtner A, Bründl J, Koch D, Wieland WF, Blana A. Fourteen-year oncological and functional outcomes of high intensity focused ultrasound in localized prostate cancer. BJU Int 2013;112:322–329.
41.
Thueroff S, Chaussy C. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. J Urol 2013;190:702–710.
42.
Crouzet S, Chapelon JY, Rouvier O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, Martin X, Gelet A. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: Oncologic outcomes and morbidity in 1002 patients. Eur Urol 2014;65:907–914.
43.
Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lyonnet D, Dubernard JM. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: Factors influencing the outcome. Eur Urol 2001;40:124–129.
44.
Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006;9:439–443.
Gerelateerde artikelen
- HIFU - Ultrasound transrectaal toegepast geeft uitstekende resultaten zowel curatief als palliatief bij lokale en gevorderde uitgezaaide prostaatkanker
- HIFU - High-Intensity Focused Ultrasound is uitstekende behandeling voor niet uitgezaaide prostaatkanker, waarom blijft dit een experimentele behandeling en wordt HIFU niet vergoed vanuit basisverzekering? copy 1
- HIFU - Ultra Sound als pijnbestrijding voor in botten uitgezaaide prostaatkanker in UMC Utrecht neemt nog steeds deelnemers aan. copy 1
Plaats een reactie ...
Reageer op "HIFU - Ultrasound transrectaal toegepast geeft uitstekende resultaten zowel curatief als palliatief bij lokale en gevorderde uitgezaaide prostaatkanker"